Efficacy and safety of tislelizumab plus cetuximab and irinotecan in patients with previously treated RAS wild-type advanced colorectal cancer: Preliminary findings of a phase II, single-arm study.

被引：0
|
作者：
Xu, Xiaojing
Yu, Yiyi
Wang, Yan
Cui, Yuehong
Li, Wei
Liang, Li
Li, Qian
Yu, Shan
Feng, Yi
Liu, Qing
Zhang, Pengfei
Lv, Minzhi
Liu, Tianshu
机构：
[1] Fudan Univ, Dept Oncol, Canc Ctr, Zhongshan Hosp, Shanghai, Peoples R China
[2] Fudan Univ, Zhongshan Hosp, Dept Med Oncol, Canc Ctr, Shanghai, Peoples R China
[3] Fudan Univ, Zhongshan Hosp, Dept Biostat, Canc Ctr, Shanghai, Peoples R China
[4] Fudan Univ, Zhongshan Hosp, Dept Med Oncol, Shanghai, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3566
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Efficacy and safety of tislelizumab plus cetuximab and irinotecan in patients with previously treated RAS wild-type advanced colorectal cancer: A phase II, single-arm study.
    Xu, Xiaojing
    Yu, Yiyi
    Wang, Yan
    Cui, Yuehong
    Li, Wei
    Liang, Li
    Li, Qian
    Yu, Shan
    Feng, Yi
    Liu, Qing
    Zhang, Pengfei
    Lv, Minzhi
    Liu, Tianshu
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 125 - 125
  • [2] Tislelizumab plus cetuximab and irinotecan in refractory microsatellite stable and RAS wild-type metastatic colorectal cancer: a single-arm phase 2 study
    Xu, Xiaojing
    Ai, Luoyan
    Hu, Keshu
    Liang, Li
    Lv, Minzhi
    Wang, Yan
    Cui, Yuehong
    Li, Wei
    Li, Qian
    Yu, Shan
    Feng, Yi
    Liu, Qing
    Yang, Ying
    Zhang, Jiao
    Xu, Fei
    Yu, Yiyi
    Liu, Tianshu
    NATURE COMMUNICATIONS, 2024, 15 (01)
  • [3] Phase Ib/II Study of Cetuximab plus Pembrolizumab in Patients with Advanced RAS Wild-Type Colorectal Cancer
    Fountzilas, Christos
    Bajor, David L.
    Mukherjee, Sarbajit
    Saltzman, Joel
    Witkiewicz, Agnieszka K.
    Maguire, Orla
    Minderman, Hans
    Nambiar, Ram
    Rosenheck, Hanna R.
    Knudsen, Erik S.
    Muhitch, Jason B.
    Abrams, Scott, I
    Wang, Chong
    Hutson, Alan D.
    Attwood, Kristopher
    Hicks, Karen A.
    Jurcevic, Jennifer A.
    Kalinski, Pawel
    Iyer, Renuka
    Boland, Patrick M.
    CLINICAL CANCER RESEARCH, 2021, 27 (24) : 6726 - 6736
  • [4] Phase II Single-Arm Study of Palbociclib and Cetuximab Rechallenge in Patients with KRAS/NRAS/BRAF Wild-Type Colorectal Cancer
    Sorah, Jonathan D.
    Moore, Dominic T.
    Reilley, Matthew J.
    Salem, Mohamed E.
    Triglianos, Tammy
    Sanoff, Hanna K.
    McRee, Autumn J.
    Lee, Michael S.
    ONCOLOGIST, 2022, 27 (12): : 1006 - E930
  • [5] Phase II study of cetuximab with irinotecan for KRAS wild-type colorectal cancer in Japanese patients
    Terazawa, Tetsuji
    Nishitani, Hitoshi
    Kato, Ken
    Hashimoto, Hironobu
    Akiyoshi, Kohei
    Ito, Yuriko
    Nakamoto, Akihiro
    Iwasa, Satoru
    Nakajima, Takako Eguchi
    Hamaguchi, Tetsuya
    Yamada, Yasuhide
    Shimada, Yasuhiro
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2017, 13 (02) : E132 - E137
  • [6] Cetuximab Rechallenge Plus Avelumab in Pretreated Patients With RAS Wild-type Metastatic Colorectal Cancer The Phase 2 Single-Arm Clinical CAVE Trial
    Martinelli, Erika
    Martini, Giulia
    Famiglietti, Vincenzo
    Troiani, Teresa
    Napolitano, Stefania
    Pietrantonio, Filippo
    Ciardiello, Davide
    Terminiello, Marinella
    Borrelli, Carola
    Vitiello, Pietro Paolo
    De Braud, Filippo
    Morano, Federica
    Avallone, Antonio
    Normanno, Nicola
    Nappi, Anna
    Maiello, Evaristo
    Latiano, Tiziana
    Falcone, Alfredo
    Cremolini, Chiara
    Rossini, Daniele
    Santabarbara, Giuseppe
    Pinto, Carmine
    Santini, Daniele
    Cardone, Claudia
    Zanaletti, Nicoletta
    Di Liello, Alessandra
    Renato, Daniela
    Esposito, Lucia
    Marrone, Francesca
    Ciardiello, Fortunato
    JAMA ONCOLOGY, 2021, 7 (10) : 1529 - 1535
  • [7] Cetuximab retreatment plus camrelizumab and liposomal irinotecan in patients with RAS wild-type metastatic colorectal cancer: Cohort B of the phase II CRACK study
    Quan, Ming
    Chen, Jingde
    Chen, Zhiqin
    Hai, Yannan
    Zhou, Ying
    Chao, Qian
    Chen, Chen
    Li, Huajun
    Wang, Mei
    Gao, Yong
    INTERNATIONAL JOURNAL OF CANCER, 2023, 153 (11) : 1877 - 1884
  • [8] Cetuximab Rechallenge Plus Avelumab in Pretreated Patients With RAS Wild-type Metastatic Colorectal Cancer The Phase 2 Single-Arm Clinical CAVE Trial RESPONSE
    Johnson, Douglas B.
    Patrinely, J. Randall, Jr.
    Ye, Fei
    JAMA ONCOLOGY, 2021,
  • [9] Rechallenge for Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer With Acquired Resistance to First-line Cetuximab and Irinotecan A Phase 2 Single-Arm Clinical Trial
    Cremolini, Chiara
    Rossini, Daniele
    Dell'Aquila, Emanuela
    Lonardi, Sara
    Conca, Elena
    Del Re, Marzia
    Busico, Adele
    Pietrantonio, Filippo
    Danesi, Romano
    Aprile, Giuseppe
    Tamburini, Emiliano
    Barone, Carlo
    Masi, Gianluca
    Pantano, Francesco
    Pucci, Francesca
    Corsi, Domenico C.
    Pella, Nicoletta
    Bergamo, Francesca
    Rofi, Eleonora
    Barbara, Cecilia
    Falcone, Alfredo
    Santini, Daniele
    JAMA ONCOLOGY, 2019, 5 (03) : 343 - 350
  • [10] A phase Ib study of cetuximab combined with fruquintinib in the previously treated RAS/BRAF wild-type metastatic colorectal cancer: The preliminary result of CEFRU study
    Li, Y.
    Chen, X.
    Liu, Y. H.
    Qu, X.
    Ye, Y. S.
    Sun, S. D.
    Chen, Y. D.
    Zhang, H. B.
    ANNALS OF ONCOLOGY, 2021, 32 : S572 - S572
12345